Myungin Pharm

317450 · KOSPI · ₩317450 · 명인제약

₩40,200▲ ₩300 (0.75%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩114,072

vs the current price (₩40,200)

Enterprise value
₩1.2T
Equity value
₩1.7T
WACC
7.3%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Why the model and the price differ

The model is 184% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:

  • To match today's price of ₩40,200, the model needs an operating margin of 6.3% every year (it uses 32.2%).

Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.

Bear / Base / Bull

Bear
₩88,607
+120.4%
Base
₩114,072
+183.8%
Bull
₩155,504
+286.8%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (32.2%).

Revenue growth

  • 3%

    How much sales grow that year, compared with the year before.

    Default: not enough revenue history, so 3%.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: not enough revenue history, so 3%.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: not enough revenue history, so 3%.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: not enough revenue history, so 3%.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: not enough revenue history, so 3%.

Business

  • 32.2%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 1 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 9.7%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).

  • 12.1%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 1 annual reports (cash flow statements; equipment and intangibles).

  • 38.1%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 1 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.03%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-27.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 56 weeks of weekly returns against KOSPI (official index); raw beta 0.13, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.53%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩287B
Net debt (borrowings and leases − cash and deposits)
−₩447B
+ Stakes and investments
₩5M
Associates, long-term financial assets and deposits (book value)
Shares
14,600,000
Share price
₩40,200
Market cap
₩587B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩287B₩296B₩305B₩314B₩323B₩333B
Growth—3.0%3.0%3.0%3.0%3.0%
EBIT₩92B₩95B₩98B₩101B₩104B₩107B
EBIT margin32.2%32.2%32.2%32.2%32.2%32.2%
After-tax EBIT₩67B₩69B₩71B₩73B₩75B₩78B
+ Depreciation—₩29B₩30B₩30B₩31B₩32B
− Capital spending₩35B₩36B₩37B₩38B₩39B₩40B
− Working capital—₩3.3B₩3.4B₩3.5B₩3.6B₩3.7B
Free cash flow—₩59B₩60B₩62B₩64B₩66B
Discount factor—0.9320.8680.8090.7530.702
Present value—₩55B₩52B₩50B₩48B₩46B

Terminal value ₩1.4T, worth ₩967B today: 79% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
6.3%₩118,255₩125,199₩133,739₩144,499₩158,478
6.8%₩110,538₩116,136₩122,886₩131,187₩141,646
7.3%₩104,044₩108,631₩114,072₩120,634₩128,703
7.8%₩98,504₩102,315₩106,774₩112,063₩118,442
8.3%₩93,724₩96,927₩100,631₩104,966₩110,108

Now (TTM)

Market cap
₩587B
Enterprise value
₩139B
P/E
7.2×
P/B
0.7×
P/S
2.0×
EV/EBITDA
—
Dividend yield
3.7%

Over time (at each year end)

2025
Price₩68,900
Market cap₩1T
P/E12.4×
P/B1.3×
P/S3.5×
EV/EBITDA—
Dividend yield2.2%

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Myungin Pharm7.2×0.7×2.0×—3.7%
Samsung Biologics32.1×7.6×14.0×—0.0%
Celltrion27.8×2.4×8.9×—0.0%
Alteogen78.8×28.4×59.9×—0.1%
Yuhan24.8×2.5×2.6×32.5×0.8%
SK biopharmaceuticals14.6×5.7×6.8×—0.0%
HLB—15.4×54.6×—0.0%
Similar companies (median)27.8×6.7×11.5×32.5×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Myungin Pharm / 명인제약 / 317450 / KRX:317450

Source: KRX statistical information